Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Alumis Inc. Common Stock

A company that transforms the lives of patients living with immune-mediated diseases using a precision approach to develop oral therapies.

Alumis

At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.

We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. 

Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. 

Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.

Today we announced the pricing of our initial public offering: https://bit.ly/3zwhdvh #NasdaqListed

Today, we honor #Juneteenth, celebrating freedom, resilience, and progress. As we reflect on this important day in history, we’re committed to fostering diversity and inclusion at Alumis. #FreedomDay

Alumis’ clinical development team attended the EULAR - European Alliance of Associations for Rheumatology 2024 Congress earlier this month in Vienna! With the goal of driving progress in the clinical care of people with rheumatic diseases, the annual meeting brings together patients, health professionals, rheumatologists and industry partners to showcase the latest scientific breakthroughs in clinical, translational, and basic research. We were thrilled to be part of this meeting as we advance our #lupus clinical trial LUMUS! #EULAR2024

This #PrideMonth, we celebrate the vibrant LGBTQIA+ community and recognize their invaluable contributions to science and biotechnology. Together, we stand proud in our commitment to diversity, inclusion, and equality. #Pride2024

Did you know that women are disproportionately affected by #lupus? To learn more about lupus this #LupusAwarenessMonth, check out resources and information from @LupusResearch: https://lnkd.in/esmUVvvw

We are thrilled to announce our initial public offering, trading on Nasdaq under the ticker $ALMS! This achievement wouldn't have been possible without the relentless dedication of our incredible team, as well as the support of our Board of Directors and investors. Thank you to everyone who helped us reach this critical milestone in support of our mission to improve the lives of patients with immune-mediated diseases. #NasdaqListed

	Dec '22	Dec '23
net income	-111.93M -	-154.99M 38.47%
depreciation and amortization	250K -	1.28M 413.60%
deferred income tax
stock based compensation	5.96M -	8.63M 44.71%
change in working capital	-1.92M -	12.06M 729.33%
accounts receivables
inventory
accounts payables	1.29M -	-642K 149.61%
other working capital	-1.92M -	12.06M 729.33%
other non cash items	6.37M -	14.24M 123.47%
net cash provided by operating activities	-107.72M -	-129.97M 20.66%
investments in property plant and equipment	-2.41M -	-4.50M 86.99%
acquisitions net
purchases of investments	-209.07M -	-11.28M 94.61%
sales maturities of investments	142.73M -	76.25M 46.58%
other investing activites	-66.34M -	64.97M 197.93%
net cash used for investing activites	-68.75M -	60.47M 187.96%
debt repayment
common stock issued	101.63M -	90.23M 11.21%
common stock repurchased		-64K -
dividends paid
other financing activites	101.63M -	-485K 100.48%
net cash used provided by financing activities	101.63M -	89.68M 11.75%
effect of forex changes on cash
net change in cash	-75.98M -	20.29M 126.71%
cash at beginning of period	101.80M -	25.82M 74.64%
cash at end of period	25.82M -	46.11M 78.61%
operating cash flow	-107.72M -	-129.97M 20.66%
capital expenditure	-2.41M -	-4.50M 86.99%
free cash flow	-110.13M -	-134.47M 22.11%

ALMS

COM:ALUMIS

Alumis

Last Close

9.64

21/11 21:00

Market Cap

668.34M

Beta: -

Volume Today

80.08K

Avg: -

Preview